Moreover, mouse models of pancreas cancer have been used to identify possible combinations of PARP inhibitors with PD-L1/PD-1 inhibitors (119), providing rationale for the design of novel clinical trials specifically for BRCA-mutant pancreas cancer patients. The gene discussed is CD274; the disease is pancreatic neoplasm.